Flonase is an allergy medication — specifically, an intranasal corticosteroid (INCS) used to treat allergic rhinitis and its associated nasal symptoms. In the UK, the same active ingredient, fluticasone propionate, is more commonly found under the brand name Flixonase or as a generic nasal spray. Recommended as a first-line treatment by NICE and the BSACI, fluticasone nasal spray works by reducing inflammation in the nasal passages rather than simply blocking histamine. This article explains how fluticasone is classified, what conditions it treats, how to use it safely, and when to seek further medical advice.

What Is Flonase and How Is It Classified in the UK?

Flonase's active ingredient, fluticasone propionate, is classified as an intranasal corticosteroid and is marketed in the UK as Flixonase; it is a first-line allergy treatment for allergic rhinitis per NICE and BSACI guidance.

Flonase is a brand name widely recognised in North America for a nasal spray containing fluticasone propionate, a synthetic corticosteroid. In the United Kingdom, the same active ingredient is more commonly marketed under the brand name Flixonase, and is also available as a generic fluticasone propionate nasal spray. A related but distinct compound, fluticasone furoate, is marketed as Avamys; although both belong to the fluticasone family, they have different dosing schedules, age-licensing, and are not interchangeable without prescriber advice. All of these products are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

Regarding availability: fluticasone propionate nasal sprays are available on NHS prescription and, in certain formulations, as pharmacy-only (P) medicines over the counter. It is important to note that over-the-counter fluticasone propionate nasal sprays are generally licensed for adults aged 18 and over only. Use in children and adolescents under 18 requires a prescription and should be supervised by a healthcare professional.

Fluticasone propionate belongs to the corticosteroid class of medicines. When used as a nasal spray, it acts locally within the nasal passages rather than being significantly absorbed into the bloodstream, which means it carries a much lower risk of systemic side effects compared with oral steroids. Its primary mechanism of action involves binding to glucocorticoid receptors in nasal tissue, thereby reducing the release of inflammatory mediators — including histamine, prostaglandins, and cytokines — that drive allergic and inflammatory responses.

Experiencing these side effects? our pharmacists can help you navigate them →

To answer the question directly: yes, fluticasone nasal spray (the UK equivalent of Flonase) is classified as an allergy medication, specifically an intranasal corticosteroid (INCS). It is considered a first-line pharmacological treatment for allergic rhinitis by both NICE (CKS: Allergic Rhinitis) and the British Society for Allergy and Clinical Immunology (BSACI). It is distinct from antihistamines in that it works by suppressing the underlying inflammatory cascade rather than simply blocking histamine receptors, making it particularly effective for persistent or moderate-to-severe nasal allergy symptoms.

Conditions Fluticasone Nasal Spray Is Used to Treat

Fluticasone nasal spray is primarily licensed for seasonal and perennial allergic rhinitis, relieving nasal congestion, rhinorrhoea, sneezing, and nasal itching; it is not licensed for nasal polyps in its standard aqueous spray formulation.

The primary licensed indication for fluticasone propionate nasal spray is allergic rhinitis, which encompasses both seasonal allergic rhinitis (commonly known as hay fever) and perennial allergic rhinitis (year-round nasal allergy). Perennial allergic rhinitis is often triggered by house dust mites, pet dander, or mould. Allergic rhinitis affects approximately one in five people in the UK and can significantly impair quality of life, sleep, and daytime functioning. NICE guidance (CKS: Allergic Rhinitis) recommends intranasal corticosteroids such as fluticasone as the preferred treatment for moderate-to-severe or persistent symptoms, particularly when nasal congestion is a prominent feature.

Fluticasone nasal spray is effective against a broad range of nasal allergy symptoms, including:

• Nasal congestion and blockage

• Rhinorrhoea (runny nose)

• Sneezing

• Nasal itching

• Post-nasal drip

In some cases, it may also provide modest relief of associated ocular symptoms such as itchy or watery eyes, though antihistamine eye drops may be needed for more pronounced eye involvement.

Fluticasone propionate nasal spray is sometimes used by clinicians in the management of non-allergic (vasomotor) rhinitis; however, this is an off-label use and the evidence base is variable. Patients should discuss this with their GP or specialist rather than self-treating.

Regarding nasal polyps: it is important to note that standard fluticasone propionate aqueous nasal sprays are not licensed for the treatment of nasal polyps. Fluticasone propionate nasal drops (nasules) are the licensed formulation for this indication, and their use is guided by NICE NG149 (Chronic Rhinosinusitis, including Nasal Polyps). Management of nasal polyps should be directed by a GP or ENT specialist.

Fluticasone nasal spray is not indicated for acute bacterial infections such as sinusitis, nor is it a treatment for asthma when used in its nasal formulation. Patients with co-existing asthma may be prescribed a separate inhaled corticosteroid for their lower airway disease, and it is important not to confuse the two delivery systems or indications.

Using Fluticasone Nasal Spray Safely: Dosage and Precautions

Adults typically use two sprays per nostril once daily (200 micrograms total), reducing to one spray per nostril once controlled; caution is required with CYP3A4 inhibitors and when combining multiple corticosteroid products.

In the UK, fluticasone propionate nasal spray (50 micrograms per actuation) is typically used as follows, in line with the product Summary of Product Characteristics (SmPC) and BNF guidance:

Adults (18 and over):

• Starting dose: Two sprays into each nostril once daily (200 micrograms total), preferably in the morning

• Maintenance dose: Once symptoms are controlled, this may be reduced to one spray per nostril once daily (100 micrograms total)

• In severe cases, some adults may be advised by a clinician to use two sprays per nostril twice daily short-term; always follow the specific product SmPC or patient information leaflet

• Maximum recommended dose: 200 micrograms per nostril per day (400 micrograms total daily) — do not exceed this without medical advice

Children (prescription use only, under medical supervision):

• Children aged 4–11 years: One spray per nostril once daily (100 micrograms total), under adult supervision; dose adjustments should be prescriber-led

• OTC fluticasone propionate nasal sprays are not licensed for use in children under 18; paediatric use requires a prescription

• Note: Avamys (fluticasone furoate) has different age licensing (from age 6) and dosing; it is not interchangeable with fluticasone propionate without prescriber guidance

The spray should be directed away from the nasal septum (the central dividing wall of the nose) to reduce the risk of irritation or, in rare cases, septal perforation with prolonged use. Patients should blow their nose gently before use and prime the pump if the spray has not been used recently. Fluticasone nasal spray should not be used if there is nasal ulceration, or following recent nasal surgery or nasal trauma, until healing is complete.

Because fluticasone is a corticosteroid, certain precautions apply. Systemic absorption is low with nasal use, but caution is warranted in patients already using other corticosteroid preparations (e.g., inhaled steroids for asthma, topical steroids for skin conditions), as cumulative exposure may increase the risk of adrenal suppression, particularly in children. The MHRA advises that the lowest effective dose should be used, especially in paediatric patients. In children receiving prolonged treatment, growth should be monitored regularly by a healthcare professional.

Important drug interactions: Fluticasone propionate is metabolised by the CYP3A4 enzyme. Strong CYP3A4 inhibitors — including ritonavir, cobicistat, itraconazole, ketoconazole, and clarithromycin — can significantly increase fluticasone blood levels and raise the risk of systemic corticosteroid effects, including adrenal suppression. The MHRA has issued Drug Safety Updates on this risk. Patients taking any of these medicines should inform their prescriber or pharmacist before using fluticasone.

Worried about interactions with other medications? speak to one of our pharmacists →

Common side effects include:

• Nasal dryness or irritation

• Epistaxis (nosebleeds) — usually mild

• Headache

• Unpleasant taste or smell

If you experience any suspected side effects, you can report them directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Fluticasone nasal spray is generally considered safe in pregnancy when used at recommended doses, but patients who are pregnant or breastfeeding should seek pharmacist or GP advice before starting treatment. It should not be used in patients with untreated nasal infections. Full therapeutic benefit may take several days to become apparent, so patients should be encouraged to use it consistently rather than on an as-needed basis.

When to Seek Further Advice From a GP or Pharmacist

Seek GP or pharmacist advice if symptoms do not improve after 2–4 weeks, if one-sided nasal symptoms occur, or if you are taking strong CYP3A4 inhibitors such as ritonavir or cobicistat alongside fluticasone.

For many adults, fluticasone nasal spray purchased over the counter will effectively manage mild-to-moderate allergic rhinitis without the need for a GP appointment. However, there are several circumstances in which professional advice should be sought promptly.

Contact a pharmacist or GP if:

• Symptoms do not improve after 2–4 weeks of consistent use at the recommended dose

• You experience frequent or heavy nosebleeds, persistent nasal crusting, or any change in the appearance of the nasal passages

• You develop new or worsening symptoms such as facial pain, fever, or discoloured nasal discharge, which may suggest a secondary bacterial infection requiring separate treatment

• You have persistent symptoms affecting only one side of the nose, or one-sided nasal discharge, which should always be assessed by a clinician

• You are taking other medications, particularly ritonavir, cobicistat, or other strong CYP3A4 inhibitors, as these can significantly increase fluticasone blood levels and raise the risk of systemic corticosteroid effects

• You are using multiple corticosteroid products simultaneously and are concerned about cumulative exposure

Seek urgent medical attention if you experience visual disturbances, periorbital (around the eye) swelling, severe headache, or signs of adrenal insufficiency (such as unusual fatigue, dizziness, or unexplained weight loss), as these may — rarely — indicate excessive systemic corticosteroid absorption or a serious complication requiring prompt assessment.

A GP referral to an allergy specialist or ENT (ear, nose and throat) consultant may be appropriate if:

• Allergic rhinitis is severe, persistent, or significantly affecting quality of life despite optimal pharmacological management

• Allergen immunotherapy (desensitisation) is being considered

• There is diagnostic uncertainty, or nasal polyps or structural abnormalities are suspected

NICE guidance (CKS: Allergic Rhinitis) supports a stepwise approach to management. Useful additional or step-up options that a healthcare professional may consider include saline nasal irrigation, antihistamine nasal sprays, or combination intranasal antihistamine/corticosteroid sprays (such as azelastine/fluticasone). Oral antihistamines may also be used alongside intranasal corticosteroids for broader symptom control.

Leukotriene receptor antagonists (such as montelukast) are not routinely recommended for allergic rhinitis alone in the UK. They may be considered by a clinician where there is co-existing asthma, but the MHRA has issued a Drug Safety Update highlighting the risk of neuropsychiatric reactions with montelukast; this should be discussed with a prescriber before use.

A healthcare professional can help tailor treatment to ensure the best outcome for each individual patient.

Frequently Asked Questions